financetom
Business
financetom
/
Business
/
Qiagen Q3 Adjusted Earnings, Revenue Rise; 2025 Adjusted EPS Guidance Boosted
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Qiagen Q3 Adjusted Earnings, Revenue Rise; 2025 Adjusted EPS Guidance Boosted
Nov 4, 2025 10:56 AM

01:43 PM EST, 11/04/2025 (MT Newswires) -- Qiagen ( QGEN ) reported Q3 adjusted earnings Tuesday of $0.61 per diluted share, up from $0.57 a year earlier.

Analysts polled by FactSet expected $0.59.

Revenue for the three months ended Sept. 30 was $532.6 million, up from $501.9 million a year earlier.

Analysts surveyed by FactSet expected $525.9 million.

The company expects Q4 net sales to remain steady and estimates adjusted EPS of $0.60, both at constant exchange rates. Analysts surveyed by FactSet expect adjusted EPS of $0.61.

The company reaffirmed its full-year 2025 net sales growth outlook of 4% to 5% and raised its adjusted EPS guidance to $2.38, at constant exchange rates, from $2.35 earlier. Analysts surveyed by FactSet expect adjusted EPS of $2.34.

Qiagen ( QGEN ) also plans to close a $500 million synthetic share repurchase in January 2026 in a bid to drive shareholder returns, the company said.

Shares of Qiagen ( QGEN ) fell 4% in recent trading.

Price: 43.86, Change: -1.83, Percent Change: -4.00

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Accenture posts fourth quarter revenue above estimates
Accenture posts fourth quarter revenue above estimates
Sep 25, 2025
Sept 25 (Reuters) - Accenture ( ACN ) on Thursday reported fourth-quarter revenue slightly above Wall Street estimates, driven by resilient demand for its artificial intelligence-driven consulting and services from enterprise clients. The company posted fourth-quarter revenue of $17.6 billion, compared with estimates of $17.36 billion, according to data compiled by LSEG. ...
Eli Lilly halts trial of experimental weight-loss drug
Eli Lilly halts trial of experimental weight-loss drug
Sep 25, 2025
Sept 25 (Reuters) - Eli Lilly ( LLY ) has halted a study of an experimental drug, which is designed to prevent obesity patients from losing too much muscle, due to strategic business reasons, according to a U.S. registry of clinical trials. The drugmaker was testing the drug, bimagrumab, alone or in combination with Lilly's tirzepatide, the active ingredient in...
Accenture posts fourth quarter revenue above estimates
Accenture posts fourth quarter revenue above estimates
Sep 25, 2025
(Reuters) -Accenture ( ACN ) on Thursday reported fourth-quarter revenue slightly above Wall Street estimates, driven by resilient demand from enterprise clients for its AI-driven consulting and services. Shares of the Dublin-based company were up 3.7% in choppy premarket trading. Businesses are scaling up AI projects, digitizing core operations and prioritizing data security to drive growth and cut costs, trends...
Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering
Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering
Sep 25, 2025
Fort Lauderdale, FL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition II Corp. (the “Company”) announced today the pricing yesterday of its initial public offering of 50,000,000 units at $10.00 per unit. The units are expected to be listed on The Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “DMIIU” beginning September 25, 2025. Each unit...
Copyright 2023-2026 - www.financetom.com All Rights Reserved